Hong Kong Pharma (HKPD) | Financial Analysis & Statements
Hong Kong Pharma Digital Technology Co. Ltd. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
9.4M
Total Liabilities
4.4M
Shareholders Equity
5.0M
Debt to Equity
0.89
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2025
Hong Kong Pharma Income Statement From 2023 to 2025
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 20.3M | 16.7M | 12.6M |
| Cost of Goods Sold | 17.9M | 13.1M | 9.8M |
| Gross Profit | 2.4M | 3.6M | 2.7M |
| Gross Margin % | 11.9% | 21.3% | 21.8% |
| Operating Expenses | |||
| Research & Development | - | - | - |
| Selling, General & Administrative | 2.2M | 1.9M | 1.8M |
| Other Operating Expenses | -1.5K | -4.0K | -96.2K |
| Total Operating Expenses | 2.2M | 1.9M | 1.7M |
| Operating Income | 200.8K | 1.7M | 1.1M |
| Operating Margin % | 1.0% | 10.0% | 8.6% |
| Non-Operating Items | |||
| Interest Income | 1.7K | 474 | 219 |
| Interest Expense | 97.7K | 82.8K | 23.2K |
| Other Non-Operating Income | -68.7K | -65.0K | -33.3K |
| Pre-tax Income | 36.1K | 1.5M | 1.0M |
| Income Tax | 63.2K | 196.3K | 22.6K |
| Effective Tax Rate % | 174.9% | 12.9% | 2.2% |
| Net Income | -27.1K | 1.3M | 998.2K |
| Net Margin % | -0.1% | 8.0% | 7.9% |
| Key Metrics | |||
| EBITDA | 1.3M | 2.6M | 1.8M |
| EPS (Basic) | $0.00 | $0.12 | $0.09 |
| EPS (Diluted) | $0.00 | $0.12 | $0.09 |
| Basic Shares Outstanding | 10205479 | 11000000 | 11000000 |
| Diluted Shares Outstanding | 10205479 | 11000000 | 11000000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Hong Kong Pharma Balance Sheet From 2023 to 2025
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Assets | |||
| Current Assets | |||
| Cash & Equivalents | 748.7K | 619.6K | 524.6K |
| Short-term Investments | 2.3M | 0 | - |
| Accounts Receivable | 4.7M | 3.7M | 1.6M |
| Inventory | 560.0K | 933.3K | 190.9K |
| Other Current Assets | - | - | - |
| Total Current Assets | 8.7M | 7.8M | 2.7M |
| Non-Current Assets | |||
| Property, Plant & Equipment | 650.4K | 855.1K | 599.7K |
| Goodwill | 96.4K | 31.8K | 4.0K |
| Intangible Assets | 96.4K | 31.8K | 4.0K |
| Long-term Investments | - | - | - |
| Other Non-Current Assets | - | - | - |
| Total Non-Current Assets | 690.2K | 865.5K | 658.3K |
| Total Assets | 9.4M | 8.7M | 3.4M |
| Liabilities | |||
| Current Liabilities | |||
| Accounts Payable | 1.7M | 1.3M | 1.4M |
| Short-term Debt | 864.7K | 849.7K | 419.6K |
| Current Portion of Long-term Debt | - | - | - |
| Other Current Liabilities | - | - | - |
| Total Current Liabilities | 2.9M | 3.2M | 2.6M |
| Non-Current Liabilities | |||
| Long-term Debt | 1.5M | 1.2M | 271.5K |
| Deferred Tax Liabilities | - | - | - |
| Other Non-Current Liabilities | - | - | - |
| Total Non-Current Liabilities | 1.5M | 1.2M | 271.5K |
| Total Liabilities | 4.4M | 4.4M | 2.8M |
| Equity | |||
| Common Stock | 11.0K | 10.0K | 6.8K |
| Retained Earnings | 1.5M | 1.5M | 201.4K |
| Treasury Stock | - | - | - |
| Other Equity | - | - | - |
| Total Shareholders Equity | 5.0M | 4.3M | 585.2K |
| Key Metrics | |||
| Total Debt | 2.4M | 2.1M | 691.1K |
| Working Capital | 5.8M | 4.6M | 198.4K |
Balance Sheet Composition
Hong Kong Pharma Cash Flow Statement From 2023 to 2025
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | -27.1K | 1.3M | 998.2K |
| Depreciation & Amortization | 1.1M | 925.6K | 714.6K |
| Stock-Based Compensation | - | - | - |
| Working Capital Changes | -405.4K | -2.8M | -8.3K |
| Operating Cash Flow | 640.9K | -589.9K | 1.7M |
| Investing Activities | |||
| Capital Expenditures | -69.9K | -19.5K | -114.6K |
| Acquisitions | - | - | - |
| Investment Purchases | -2.3M | 0 | 0 |
| Investment Sales | - | - | - |
| Investing Cash Flow | -2.4M | -5.5K | -129.0K |
| Financing Activities | |||
| Share Repurchases | - | - | - |
| Dividends Paid | - | - | - |
| Debt Issuance | 1.6M | 2.1M | 189.2K |
| Debt Repayment | -2.5M | -1.8M | -1.3M |
| Financing Cash Flow | 2.0M | 537.3K | -1.2M |
| Free Cash Flow | 414.2K | -482.3K | 1.6M |
| Net Change in Cash | 266.2K | -58.1K | 419.8K |
Cash Flow Trend
Hong Kong Pharma Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
6.26
Price to Book
1.47
Price to Sales
0.99
Profitability Ratios
Profit Margin
-4.29%
Operating Margin
2.96%
Return on Equity
-13.38%
Return on Assets
-3.94%
Financial Health
Current Ratio
2.93
Debt to Equity
44.19
Per Share Data
EPS (TTM)
$-0.06
Book Value per Share
$0.47
Revenue per Share
$1.53
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| HKPD | 14.6M | 6.26 | 1.47 | -13.38% | -4.29% | 44.19 |
| Walgreens Boots | 10.4B | 27.10 | 1.44 | -69.58% | -4.07% | 409.88 |
| High Tide | 211.0M | -3.89 | 3.26 | -39.72% | -7.42% | 110.31 |
| PetMed Express | 47.7M | 257.00 | 1.50 | -100.61% | -34.70% | 1.99 |
| Wellgistics Health | 17.3M | - | - | 813.59% | -27.54% | -1.97 |
| Scienture Holdings | 17.0M | 0.56 | 0.24 | -55.65% | 76.80% | 0.03 |
Financial data is updated regularly. All figures are in the company's reporting currency.





